^
BIOMARKER:

TP53 mutation

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1




Show legend

Include preclinical:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Acute Myelogenous Leukemia
Non Small Cell Lung Cancer
Myelodysplastic Syndrome
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma
Colorectal Cancer
Ovarian Cancer
B Acute Lymphoblastic Leukemia
Squamous Cell Carcinoma of Head and Neck
Lung Adenocarcinoma
Solid Tumor
Urothelial Cancer
Triple Negative Breast Cancer
Endometrial Cancer
Multiple Myeloma
Lymphoma
Pancreatic Adenocarcinoma
T Acute Lymphoblastic Leukemia
Lung Non-Squamous Non-Small Cell Cancer
Pancreatic Cancer
Leiomyosarcoma
Esophageal Squamous Cell Carcinoma
Glioblastoma
Chronic Myelomonocytic Leukemia
Non-Hodgkin’s Lymphoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Gastrointestinal Stromal Tumor
Neuroendocrine Tumor
Squamous Cell Skin Cancer
Glioma
Clear Cell Renal Cell Carcinoma
Gastroesophageal Cancer
Biliary Tract Cancer
Melanoma
Prostate Cancer
Renal Cell Carcinoma
Medulloblastoma
HER2 Positive Breast Cancer
Breast Cancer
Marginal Zone Lymphoma
Cholangiocarcinoma
Hormone Receptor Positive Breast Cancer
HER2 Negative Breast Cancer
Germ Cell Tumors
Hepatocellular Cancer
Neurofibrosarcoma
Bladder Cancer
Follicular Lymphoma
Peripheral T-cell Lymphoma
Colon Cancer
Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Acute Lymphocytic Leukemia
Esophageal Adenocarcinoma
Hairy Cell Leukemia
pembrolizumab
pirtobrutinib
zanubrutinib
rituximab + lenalidomide
obinutuzumab + acalabrutinib
alemtuzumab
rituximab + alemtuzumab
duvelisib
nivolumab
obinutuzumab
rituximab
idelalisib
lenalidomide
Immunotherapy + lenalidomide
pembrolizumab + nivolumab + ibrutinib
venetoclax
AZD1775
bevacizumab + atezolizumab
ibrutinib + ublituximab-xiiy
venetoclax + ibrutinib
orelabrutinib
venetoclax + obinutuzumab
rituximab + idelalisib
acalabrutinib
venetoclax + rituximab
ibrutinib
pembrolizumab + ibrutinib
APR-246
GS-4721
decitabine
ibrutinib + rituximab
LY3143921
cytarabine/daunorubicin liposomal formulation
inotuzumab ozogamicin
MBG453
ibrutinib + lisocabtagene maraleucel
pembrolizumab + APR-246
venetoclax + tagraxofusp-erzs
tagraxofusp-erzs
ibrutinib + UC-961
M6620
etoposide IV + decitabine
M7583
venetoclax + ABBV-621
afatinib
nivolumab + ipilimumab
chidamide
everolimus
dasatinib
temozolomide + rivoceranib
Orca-T
venetoclax + ibrutinib + obinutuzumab
nivolumab + ibrutinib
rituximab + lenalidomide + acalabrutinib
temozolomide gel
ALX148
lintuzumab-Ac225
ORY-1001
venetoclax + duvelisib
TP-0903
obinutuzumab + GS-9973
axicabtagene ciloleucel
A-1331852
ABT 263
nintedanib
HB0030
venetoclax + ibrutinib + rituximab
venetoclax + lintuzumab-Ac225
venetoclax + APR-246
GS-9973
melphalan flufenamide
olaparib + capivasertib
rituximab + lenalidomide + penpulimab
idelalisib + ofatumumab
crizotinib
cytarabine + decitabine + tretinoin
epcoritamab-bysp
eribulin mesylate
osimertinib + APG-1252
dostarlimab-gxly
SCT200
I-131-apamistamab
venetoclax + ruxolitinib
lisocabtagene maraleucel
venetoclax + GS-4721
enfortumab vedotin-ejfv
rituximab + zanubrutinib
venetoclax + obinutuzumab + zanubrutinib
gemcitabine + albumin-bound paclitaxel
venetoclax + RG7388
venetoclax + rituximab + lenalidomide
bevacizumab
ibrutinib + rituximab + lenalidomide
bevacizumab + gefitinib
selinexor
bevacizumab + cetuximab
venetoclax + MLN4924
cetuximab
ADX-1612
aumolertinib
lorlatinib
bevacizumab + erlotinib
blinatumomab
pazopanib
azacitidine + MBG453
venetoclax + obinutuzumab + acalabrutinib
decitabine + MBG453
cytarabine + idarubicin hydrochloride
RP6530
MGD006
CFI-400945
CB-839
chlorambucil
venetoclax + bortezomib
Immunotherapy
cisplatin
purinostat
capecitabine
T-lymphocyte cell therapy
ABCP
CD7-targeted CAR-T immunotherapy
YF2
crizotinib + sunitinib
PI3K inhibitor
venetoclax + VRx-510
oxaliplatin
NSC-324360
AZD1775 + VIC-1911
AGK2
gefitinib
LY294002
venetoclax + SM09419
SM09419
VE-821
CX-5461 + VE-821
ENMD-2076
FL118
SC0191
venetoclax + AZD5991
AZD5991
COTI-2
BIBR1532
midostaurin
doxorubicin hydrochloride
AZD1775 + SRA737
AZD1390
CUDC-907
AN2025 + panobinostat
panobinostat
AN2025
AN2025 + sirolimus
INCB57643
cytarabine
R-CHOP
Nutlin-3
PD1 inhibitor
CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
ofatumumab
blinatumomab + inotuzumab ozogamicin
decitabine/cedazuridine
azacitidine
FGFR inhibitor
dacarbazine
osimertinib
gemcitabine + toripalimab-tpzi
SGR-2921
capivasertib + AZD8055
abiraterone acetate
abiraterone acetate + RG7440
enzalutamide capsule
GDC-0032
FCR
docetaxel
ACY-1215
toripalimab-tpzi
FOLFIRINOX
FOLFOX
talazoparib
erdafitinib
sunitinib
fulvestrant
eribulin mesylate + selinexor
rituximab + cladribine
DCAG
AZD1775 + ACY-1215
BMF-219
BTK inhibitor
tisagenlecleucel-T
palbociclib
BR
trastuzumab
docetaxel + cyclophosphamide + eribulin mesylate
PD1 inhibitor + Angiogenesis inhibitor
VEGFR inhibitor
DHODH inhibitor
tislelizumab + zanubrutinib
gemtuzumab ozogamicin
CHOP
CDK4 inhibitor + CDK6 inhibitor
FLAG-IDA
tamoxifen
ASP7487
trametinib
atezolizumab
RG7388
ViPOR
anlotinib
lenvatinib
venetoclax + NTX-301
BOVen
M3814 + VP-006
bortezomib